Discussions Begin on Collaborative Genomic Drug Discovery Support Using the IQVIA Genome Wide Study Platform

2023.07.06

Axcelead Drug Discovery Partners Inc. (Headquarters: Fujisawa, Kanagawa; President and CEO: Nobuhiko Yamada; hereinafter, “Axcelead DDP”) and IQVIA Solutions Japan Co., Ltd. (Headquarters:  Minato-ku, Tokyo; President: Fumihiko Ugajin; hereinafter, “IQVIA”) have entered discussions regarding a collaboration on genomic drug discovery support utilizing IQVIA’s genetic database, the IQVIA Genome Wide Study Platform (hereinafter, “GWSP”).

GWSP integrates multiple genetic databases in Japan and is currently capable of performing correlation analyses of genetic information and health-related information of up to 130,000 people. GWSP makes it possible to easily search genome-wide association study (GWAS) data by disease name, gene name and single nucleotide polymorphism (SNP) IDs. The platform’s distinctive feature is that it makes it possible to obtain data reflecting gender, regional and ethnic specificity. We plan to use GWSP to analyze genetic information and thereby search for novel drug targets, biomarkers and candidate diseases. If new candidates are discovered, we will verify the results using clinical samples while performing additional investigations via IQVIA to assess the potential of genomic drug discovery support services.

Nobuhiko Yamada, President and CEO of Axcelead DDP, said “The identification of novel drug targets and biomarkers using genetic databases is crucial if we are to increase the success rate of drug discovery, and is the area that is drawing attention. Through this collaboration with IQVIA, which has the largest gene database in Japan, we will keep striving to provide high quality genome driven drug discovery services to companies aiming to develop innovative new drugs.”

About IQVIA
IQVIA (NYSE:IQV) is a leading global provider of advanced analytics, technology solutions and clinical research services to the life sciences industry dedicated to creating intelligent connections that deliver unique and actionable insights. With approximately 86,000 employees, IQVIA conducts operations in more than 100 countries. Learn more at www.iqvia.com.

About Axcelead DDP
Axcelead DDP is the first integrated drug discovery solutions provider in the pharmaceutical industry in Japan, having succeeded the drug discovery research capabilities of Takeda Pharmaceutical Company Limited and started its business in July, 2017. The company provides integrated services, from discovery of drug targets to optimization of small- and medium-molecule drug candidates, in which the company has particular expertise, and to the process of bridging the gap to clinical development.